Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
NRSN
NeuroSense Therapeutics Ltd.
CAPPED RATING
NeuroSense Therapeutics Ltd. (NRSN) is rated D- (1.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Revisions (F).
Quantitative Factor Evaluation • Updated
Overall Rating
1.0
/ 5.0
D-
Value
C+
Factor Score
2.5
/ 5.0
Growth
D
Factor Score
1.4
/ 5.0
Profitability
F
Factor Score
0.7
/ 5.0
Momentum
F
Factor Score
0.4
/ 5.0
Revisions
F
Factor Score
0.0
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-0.4
EV / EBITDA
-0.3
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-80.6%
Price Return 12M
-90.9%
Catalyst Signal
0.00
Market Cap
$3.3M
TTM Revenue
N/A
Price / Sales
N/A
ROE
N/M
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.5) | D (1.4) | F (0.7) | F (0.4) | F (0.0) | D- (1.0) |
| 2026-11-06 | C+ (2.5) | D (1.4) | F (0.7) | F (0.4) | F (0.0) | D- (1.0) |
| 2026-10-30 | C+ (2.5) | D (1.4) | D- (0.7) | F (0.5) | C+ (2.7) | D+ (1.6) |
| 2026-10-23 | C+ (2.5) | D (1.4) | F (0.7) | F (0.6) | C+ (2.6) | D+ (1.6) |
| 2026-10-16 | C+ (2.5) | D (1.4) | F (0.7) | F (0.6) | C+ (2.6) | D+ (1.6) |
Page
1
of
4